Methylation of cancer related genes in tumor and peripheral blood DNA from the same breast cancer patient as two independent events
- Tomasz K Wojdacz1, 2, 3Email author,
- Britta B Thestrup3,
- Jens Overgaard†2, 3 and
- Lise Lotte Hansen†3
© Wojdacz et al; licensee BioMed Central Ltd. 2011
Received: 8 November 2011
Accepted: 30 November 2011
Published: 30 November 2011
Recently it has been suggested that acquisition of methylation of the BRCA1 promoter detectable in peripheral blood (PB) DNA, could give raise to development of breast cancer. In this study, we aimed to investigate a relationship between methylation of three breast cancer related genes in PB DNA, and tumor specific (somatic) methylation of these genes in the same individual.
We have examined methylation status of the BRCA1, APC and RASSF1A promoter regions in a panel of 75 breast tumor and PB DNA samples from the same individual. In our study group, 4.0% of the patients displayed methylation of BRCA1 and APC in both tumor and the corresponding PB DNA. At the same time despite of marked methylation in tumor DNA, no methylation of BRCA1 and APC was seen in PB DNA of 4.3% and 2.7% of the patients respectively. The RASSF1A promoter did not show methylation in PB DNA.
Our results show that for at least a subset of cancer patients methylation of certain cancer related genes in PB DNA does not seem to be directly linked to somatic methylation of the same genes in tumor DNA, and therefore may only be specific to PB DNA.
The mechanism of methylation dependent gene deactivation and its significance to cancer pathogenesis is well described, with hypermethylation of tumor suppressor genes, affecting transcriptional activity of the genes, considered to be one of the most important drivers of carcinogenesis. Recently, much attention is paid to the phenomenon of hypermethylation of disease related genes in peripheral blood (PB) DNA and its involvement in the pathology of cancer and other diseases [1–6]. The origins of this phenomenon are unknown. However, it can be hypothesized that aberrant methylation of genes in PB DNA may be a consequence of germ line transmitted methylation changes or somatic aberrations that occurred during early development or through life time under specific environmental conditions. Transmission of methylation changes through germ line is still a problematic notion. There are only limited evidence showing that methylation of certain genes e.g. MLH1 in some cases can be passed through germ line in non-Mendelian fashion [7–11]. Recently, two studies have shown that paternal diet can have an influence on the methylation pattern of the offspring [12, 13]. This further supports the significance of germ line transmission of methylation changes, however, these findings have to be more extensively researched in the future. As for environmental pressure on the individuals methylome, the influence of different chemicals on the somatic methylation pattern of the exposed subjects has been demonstrated in animal models, and proven to be especially damaging when the exposure occurred in the early stages of development (as reviewed in ). In humans there is mounting epidemiological evidence that environmental exposure can predispose to adult onset diseases. However it is still not clear, how the interactions between individual organisms and the environment occur, and to what extent they involve methylation changes.
Disregarding the origin, the intra individual methylation differences in human PB DNA are being increasingly reported in the literature [4–6]. Furthermore, these changes have been suggested to be a part of a disease predisposition mechanism, which could be based on the theory of constitutional methylation .
Constitutional gene methylation was initially defined as abnormal gene methylation observed in all tissues of the body . Constitutional methylation is most likely affecting genes in a mono allelic fashion and if acquired during development, it can be distributed to all tissues of the organism in a mosaic pattern (and therefore seen at very low levels in affected tissues) [2, 4]. Drawing analogy from somatic methylation in cancer, constitutional mono allelic methylation changes are likely to render the affected individual prone to development of neoplastic (and other) diseases. This is due to the fact that only one additional hit would be required (according to Knudson's hypothesis of tumor suppressor deactivation ) to abolish expression of the constitutionally mono allelic methylated gene and initiate or contribute to carcinogenesis. Moreover, allelic insufficiency could also be a disease-initiating factor.
In the first report, suggesting a link between methylation of the BRCA1 promoter in PB DNA and development of breast cancer with methylated BRCA1, the authors examined methylation status of the BRCA1 promoter in tumors and PB DNA from three breast cancer patients . They showed that the BRCA1 promoter was methylated in both PB DNA samples and matched tumor DNA in all examined individuals . The observed methylation was never seen at a level suggesting monoallelic specificity (50% methylation) but only at low levels (5-14%) reflecting high degree of mosaicism in the screened cell populations. Despite the promising results of this study showing a putative elegant mechanism of direct contribution of constitutional methylation to carcinogenesis, two follow up studies did not result in similar conclusions. In those studies the authors have examined methylation status of the BRCA1 promoter in PB and paired tumor DNA, however only a subset of the tumors, developed by patients with PB BRCA1 methylation, harbored tumor specific methylation of BRCA1 [2, 17]. The study by Wong et al.  involved 12 breast cancer patients with paired tumor and PB DNA samples. The authors in this study reported generally low levels of methylation detected in PB (for most of the samples less than 5%) and furthermore, three patients with BRCA1 methylation in PB DNA did not display BRCA1 methylation in the paired tumor sample. A subsequent study by Iwamoto et al.  showed a more significant lack of direct correlation between methylation of BRCA1 in PB DNA and matched tumor samples.
Based upon the above results we aimed to investigate the presence or absence of a correlation between DNA methylation of cancer related genes in PB and paired tumor DNA from breast cancer patients.
We hypothesized that if the observed methylation of genes in PB DNA reflects constitutional methylation, the same methylation pattern has to be present in tumor DNA (as it originates from healthy tissue harboring constitutional methylation of the specific gene). Consequently if the methylation of those genes cannot be found in tumor DNA, the methylation observed in PB DNA is only specific to PB DNA (not constitutional) and does not directly contribute (in this case) to breast carcinogenesis of the affected individual.
Frequencies of methylation of analyzed genes in PB and breast tumors.
Chromosomal region targeted by assay *
Number of paired samples used/excluded**
Methylated in both blood and tumor
Sample no. (%)
Methylated only tumor***
Methylated only PBL
Sample no. (%)
chr17:41, 277, 382-41, 277, 409
chr5:112, 073, 470-112, 073, 516
chr3:50, 377, 755-50, 378, 089
All three genes analyzed in our study showed methylation in the tumor samples suggesting as previously reported, their involvement in breast cancer pathogenesis Table 1. We observed high frequencies of methylation for all three genes, however the methylation frequencies for APC and RASSF1A were higher than reported in the literature http://www.pubmeth.org. This may be attributed either to an exceptionally high methylation prevalence in our samples or more likely to a high sensitivity of the MS-HRM technology .
Two of the examined genes, BRCA1 and APC, showed methylation in both tumor and paired PB DNA at frequencies of 4.4% and 4.1%, respectively (see Table 1 for details) with one of the paired samples showing methylation of both APC and BRCA1 in tumor and PB DNA. However, at the same time three of the samples in our panel did not show methylation of BRCA1 in tumor DNA despite marked methylation in PB DNA. The same was seen for APC in two of the samples. RASSF1A did not show methylation in any of the PB samples.
Our study shows that a direct link between methylation of cancer related genes in PB DNA and development of cancer is questionable. If a direct link existed and as previously suggested detectable in PB DNA hypermethylation was constitutional , all patients with PB DNA methylation should display the same specific methylation pattern in the paired tumor. This is due to the fact that tumor DNA originates from healthy tissue, which (similar to blood tissue) should harbor constitutional methylation that in turn would predispose the affected individual to cancer development. The fact that we have not seen the same methylation pattern for a subset of our paired samples suggests independence of the methylation events in PB DNA and during tumor development. However, at the same time basing on current results, we cannot rule out the presence of a direct link between those two events for the subset of patients displaying methylation in both PB and tumor DNA.
In conclusion, the fact that methylation of the BRCA1 gene in PB DNA correlates with increased risk of breast cancer, allows to anticipate that aberrant methylation of genes in PB and disease predisposition are linked. Especially considering the study by Iwamoto et al. and the study by Wong at al. both indicating a strong correlation between methylation of BRCA1 in PB and breast cancer incidence. However, our present and previously published results do not confirm that the mechanism of that interaction is based solely on constitutional methylation and suggests independence of those two events for at least a subset of cancer patients.
- Iwamoto T, Yamamoto N, Taguchi T, Tamaki Y, Noguchi S: BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation. Breast Cancer Res Treat. 2011, 129: 69-77. 10.1007/s10549-010-1188-1.View ArticlePubMedGoogle Scholar
- Wong EM, Southey MC, Fox SB, Brown MA, Dowty JG, Jenkins MA, Giles GG, Hopper JL, Dobrovic A: Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res (Phila). 4: 23-33.Google Scholar
- Snell C, Krypuy M, Wong EM, Loughrey MB, Dobrovic A: BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype. Breast Cancer Res. 2008, 10: R12-10.1186/bcr1858.PubMed CentralView ArticlePubMedGoogle Scholar
- Widschwendter M, Apostolidou S, Raum E, Rothenbacher D, Fiegl H, Menon U, Stegmaier C, Jacobs IJ, Brenner H: Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS ONE. 2008, 3: e2656-10.1371/journal.pone.0002656.PubMed CentralView ArticlePubMedGoogle Scholar
- Flanagan JM, Munoz-Alegre M, Henderson S, Tang T, Sun P, Johnson N, Fletcher O, Dos Santos Silva I, Peto J, Boshoff C, et al: Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients. Hum Mol Genet. 2009, 18: 1332-1342. 10.1093/hmg/ddp033.PubMed CentralView ArticlePubMedGoogle Scholar
- Woodson K, Mason J, Choi SW, Hartman T, Tangrea J, Virtamo J, Taylor PR, Albanes D: Hypomethylation of p53 in peripheral blood DNA is associated with the development of lung cancer. Cancer Epidemiol Biomarkers Prev. 2001, 10: 69-74.PubMedGoogle Scholar
- Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, Lee TY, Bodmer D, Hoenselaar E, Hendriks-Cornelissen SJ, et al: Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet. 2009, 41: 112-117. 10.1038/ng.283.View ArticlePubMedGoogle Scholar
- Chan TL, Yuen ST, Kong CK, Chan YW, Chan AS, Ng WF, Tsui WY, Lo MW, Tam WY, Li VS, Leung SY: Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat Genet. 2006, 38: 1178-1183. 10.1038/ng1866.View ArticlePubMedGoogle Scholar
- Morak M, Schackert HK, Rahner N, Betz B, Ebert M, Walldorf C, Royer-Pokora B, Schulmann K, von Knebel-Doeberitz M, Dietmaier W, et al: Further evidence for heritability of an epimutation in one of 12 cases with MLH1 promoter methylation in blood cells clinically displaying HNPCC. Eur J Hum Genet. 2008, 16: 804-811. 10.1038/ejhg.2008.25.View ArticlePubMedGoogle Scholar
- Hitchins MP, Wong JJ, Suthers G, Suter CM, Martin DI, Hawkins NJ, Ward RL: Inheritance of a cancer-associated MLH1 germ-line epimutation. N Engl J Med. 2007, 356: 697-705. 10.1056/NEJMoa064522.View ArticlePubMedGoogle Scholar
- Hitchins MP, Ward RL: Erasure of MLH1 methylation in spermatozoa-implications for epigenetic inheritance. Nat Genet. 2007, 39: 1289-10.1038/ng1107-1289.View ArticlePubMedGoogle Scholar
- Carone BR, Fauquier L, Habib N, Shea JM, Hart CE, Li R, Bock C, Li C, Gu H, Zamore PD, et al: Paternally induced transgenerational environmental reprogramming of metabolic gene expression in mammals. Cell. 143: 1084-1096.Google Scholar
- Ng SF, Lin RC, Laybutt DR, Barres R, Owens JA, Morris MJ: Chronic high-fat diet in fathers programs beta-cell dysfunction in female rat offspring. Nature. 467: 963-966.Google Scholar
- Jirtle RL, Skinner MK: Environmental epigenomics and disease susceptibility. Nat Rev Genet. 2007, 8: 253-262. 10.1038/nrg2045.View ArticlePubMedGoogle Scholar
- Dobrovic A, Kristensen LS: DNA methylation, epimutations and cancer predisposition. Int J Biochem Cell Biol. 2009, 41: 34-39. 10.1016/j.biocel.2008.09.006.View ArticlePubMedGoogle Scholar
- Knudson AG: Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol. 1996, 122: 135-140. 10.1007/BF01366952.View ArticlePubMedGoogle Scholar
- Iwamoto T, Yamamoto N, Taguchi T, Tamaki Y, Noguchi S: BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation. Breast Cancer Res Treat.Google Scholar
- Wojdacz TK, Dobrovic A, Hansen LL: Methylation-sensitive high-resolution melting. Nature Protocols. 2008, 3:Google Scholar
- Wojdacz TK, Dobrovic A: Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res. 2007, 35: e41-10.1093/nar/gkm013.PubMed CentralView ArticlePubMedGoogle Scholar
- Wojdacz TK, Thestrup BB, Cold S, Overgaard J, Hansen LL: No difference in the frequency of locus-specific methylation in the peripheral blood DNA of women diagnosed with breast cancer and age-matched controls. Future Oncology. 2011, 12 (7): 1451-1455.View ArticleGoogle Scholar
- Wojdacz TK, Moller TH, Thestrup BB, Kristensen LS, Hansen LL: Limitations and advantages of MS-HRM and bisulfite sequencing for single locus methylation studies. Expert Rev Mol Diagn. 10: 575-580.Google Scholar
- Hansen LL, Andersen J, Overgaard J, Kruse TA: Molecular genetic analysis of easily accessible breast tumour DNA, purified from tissue left over from hormone receptor measurement. APMIS. 1998, 106: 371-377. 10.1111/j.1699-0463.1998.tb01359.x.View ArticlePubMedGoogle Scholar
- Hansen LL, Yilmaz M, Overgaard J, Andersen J, Kruse TA: Allelic loss of 16q23.2-24.2 is an independent marker of good prognosis in primary breast cancer. Cancer Res. 1998, 58: 2166-2169.PubMedGoogle Scholar
- Raynor MP, Stephenson SA, Pittman KB, Walsh DC, Henderson MA, Dobrovic A: Identification of circulating tumour cells in early stage breast cancer patients using multi marker immunobead RT-PCR. J Hematol Oncol. 2009, 2: 24-10.1186/1756-8722-2-24.PubMed CentralView ArticlePubMedGoogle Scholar
- Wojdacz TK, Borgbo T, Hansen LL: Primer design versus PCR bias in methylation independent PCR amplifications. Epigenetics. 2009, 4: 231-234.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.